Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the ...
The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has evolved since radium-223 (Ra-223) was approved in the United States (2013). We examined treatment patterns and real-world overall survival (rwOS) of men with mCRPC …